SAN DIEGO, June 17, 2002 (PRIMEZONE) -- CardioDynamics (Nasdaq:CDIC), the innovator and market leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(r) noninvasive digital cardiac function monitoring systems, has scheduled a conference call and Internet webcast for Thursday, June 20, 2002 at 9:00 a.m. EST to discuss the Company's financial results for the second quarter 2002 with security analysts and institutional investors. The call will be hosted by CardioDynamics' Chief Executive Officer Michael K. Perry and Chief Financial Officer Steve P. Loomis. A press release announcing second quarter 2002 results will be released pre-market on June 20, 2002.
Conference Call and Webcast Information:
To access the conference call, dial 800-349-4174. International participants can call 706-634-7498. A replay of the call will be available for one month following the call at 800-642-1687 (Code 4300155). The international replay number is 706-645-9291. The webcast is available at http://www.irconnect.com/primecast/02/q2/cdic_2q2002.mhtml. Any questions regarding this notice should be directed to Bonnie Ortega at 800-778-4825, ext. 1005, or via e-mail, bortega@cdic.com.
About CardioDynamics:
CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The Company's primary products, the BioZ(r) Systems, are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Medical Systems Information Technologies, Spacelabs Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com.
Forward-Looking (Safe Harbor) Statement:
Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 2001 Form 10-K. The company does not undertake to update the disclosures contained in this press release.